There are currently 98 active clinical trials seeking participants for Endometrial Cancer research studies. The states with the highest number of trials for Autism participants are New York, Texas, California and Ohio.
Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
NCT04586959
Recruiting
This is a prospective, multi-center, randomized non-inferiority phase III study to evaluate if patients undergoing a minimally invasive surgery for early stage uterine cancer have cancer cells in the fluid that is obtained at the time of their surgery when a uterine manipulator is placed versus patients who do not have a uterine manipulator placed.
Gender:
Female
Ages:
Between 18 years and 90 years
Trial Updated:
08/16/2023
Locations: Cleveland Clinic, Cleveland, Ohio +4 locations
Conditions: ENDOMETRIAL CANCER
Register for Updates
Adjuvant Hypofractionated Whole Pelvis Radiation Therapy in Endometrial Cancer
NCT04458402
Recruiting
Studying adjuvant hypofractionated whole pelvis radiation therapy in Endometrial Cancer.
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/09/2021
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Endometrial Cancer
Register for Updates
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
NCT05997017
Recruiting
A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida +7 locations
Conditions: Endometrial Cancer, Endometrioid Tumor, Cancer, Tumor, Recurrent Endometrial Carcinoma, Endometrioid Endometrial Cancer
Register for Updates
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT06257264
Recruiting
This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-68501 in participants with advanced, nonresectable, or metastatic solid tumors. The study will also identify a recommended dose for expansion (RDFE) in subsequent disease directed studies. The study will be conducted in 2 parts: Part 1 (dose escalation and safety e... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri +4 locations
Conditions: Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced Solid Tumor, Endometrial Cancer, Prostate Cancer
Register for Updates
(VELA) Study of BLU-222 in Advanced Solid Tumors
NCT05252416
Recruiting
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-222, a selective inhibitor of CDK2.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas +22 locations
Conditions: CCNE1 Amplification, HER2-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Gastric Cancer, Esophageal Adenocarcinoma, Carcinosarcoma, Advanced Solid Tumors, HR+ Breast Cancer
Register for Updates
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958
Recruiting
The primary objectives of this study are to compare sacituzumab tirumotecan to Treatment of Physician's Choice (TPC) with respect to progression-free survival (PFS) per response evaluation criteria in solid tumors (RECIST 1.1), as assessed by blinded independent central review (BICR), and overall survival (OS). The primary hypotheses are that sacituzumab tirumotecan is superior to TPC with respect to PFS per RECIST 1.1, as assessed by BICR, and that sacituzumab tirumotecan is superior to TPC wit... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: MedStar Washington Hospital Center ( Site 4108), Washington, District of Columbia +42 locations
Conditions: Endometrial Cancer
Register for Updates
A Study of Patients Receiving High-Dose Rate Brachytherapy
NCT00924027
Recruiting
Background: One standard way of giving radiation is to combine external beam treatments with internal brachytherapy treatments, which involve short-range radiation therapy that gives a high dose of radiation directly to a cancer or to the area where cancer cells were removed. Brachytherapy is done by placing hollow implant device(s) into the area to be treated and then moving a radiation source into each. The type of device depends on the type of cancer and the site to be treated. These devices... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Prostate Cancer, Biliary Cancer
Register for Updates
Phase 1, Safety and Tolerability Study of XmAb®541 in Advanced Solid Tumors
NCT06276491
Recruiting
The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate effect of XmAb541 on tumor outcomes.
Gender:
All
Ages:
15 years and above
Trial Updated:
04/16/2024
Locations: Montefiore Einstein Comprehensive Cancer Center, Bronx, New York
Conditions: Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor, Ovarian Germ Cell Tumor
Register for Updates
PRO1107 in Patients With Advanced Solid Tumors
NCT06171789
Recruiting
This is a global, open-label, multicenter Phase 1/2 study to evaluate the safety, tolerability, PK, and antitumor activity of PRO1107 in patients with advanced solid tumors. This study consists of 2 parts, Part A: dose escalation and dose level expansion, and Part B: tumor specific expansion.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: HonorHealth Research Institute, Scottsdale, Arizona +3 locations
Conditions: Endometrial Cancer, Ovarian Cancer, Triple Negative Breast Cancer, GastroEsophageal Cancer, Non-small Cell Lung Cancer, Urothelial Carcinoma
Register for Updates
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
NCT05103683
Recruiting
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: UCLA - JCCC Clinical Research Unit, Los Angeles, California +3 locations
Conditions: Advanced Solid Tumor, Ovarian Cancer, Endometrial Cancer, NSCLC
Register for Updates
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
NCT05797831
Recruiting
This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy. The study will be conducted in 2 parts. Part 1 will evaluate safety and efficacy of two different doses of navtemadlin alongside an observational control arm to determine the Phase 3 navtemadlin dose. Part 2 will evaluate the efficacy and safety of navtemadlin Phase 3 dose compared to placebo.
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: Northside Hospital, Atlanta, Georgia +78 locations
Conditions: Endometrial Cancer
Register for Updates
The DETECT Study: Discovery and Evaluation of Testing for Endometrial Cancer in Tampons
NCT03538665
Recruiting
Background: Endometrial cancer is a common and deadly cancer for women. It is getting more common and deadly because risk factors like age and obesity are increasing. It is highly curable if it is identified early. But there may be no symptoms early or they may be missed. Also, this cancer is becoming more common and deadly for black women than white women. Researchers want to find better ways to take samples and test them for this cancer. They want to study this for a racially diverse populati... Read More
Gender:
Female
Ages:
Between 45 years and 99 years
Trial Updated:
04/11/2024
Locations: University of Alabama, Birmingham, Alabama
Conditions: Endometrial Cancer, Endometrial Cancer Precursors
Register for Updates